Drug Watch

Axsome Therapeutics begins a pivotal trial for AXS-14, aiming to improve fibromyalgia management and address significant patient needs.

New data reveals valbenazine (Ingrezza) shows significantly higher VMAT2 target occupancy than deutetrabenazine (Austedo XR).

Scienture's Rezenopy, the highest-dose naloxone nasal spray approved by the FDA, gains patent protection.

FDA removes suicidal ideation warnings from GLP-1 RA medications, highlighting their potential benefits in weight loss and mental health treatment.

Cassava Sciences shares insights from phase 3 trials of simufilam for Alzheimer disease, revealing potential treatment differences despite unmet primary endpoints.

FDA approves ProlivRx, a groundbreaking at-home therapy for major depressive disorder, offering new hope for patients unresponsive to traditional treatments.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a strong safety profile and potential for rapid relief in outpatient settings.

Reviva Pharmaceuticals reveals promising clinical trial data on brilaroxazine, highlighting its potential to treat negative symptoms in schizophrenia.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

MapLight Therapeutics advances treatment for Alzheimer disease psychosis with FDA Fast Track designation for ML-007C-MA, targeting hallucinations and delusions.

Biohaven's BHV-7000 fails to reduce depressive symptoms in a phase 2 proof-of-concept study.

What disease states are most prominently featured in recent research? Learn more in this exclusive article.

Check out the pipeline updates from December!

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

Reviva Pharmaceuticals announced FDA recommendations from their pre-NDA meeting on brilaroxazine for schizophrenia.

Discover new research on schizophrenia treatments, including digital therapeutics and valbenazine, showcasing significant improvements in patient outcomes.

Roche reveals promising results for trontinemab, an Alzheimer antibody, showing significant amyloid plaque reduction in patients during ongoing trials.

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.